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Background: in oral medicine, colchicine is a therapeutic alternative for idiopathic recurrent aphthous 
stomatitis (RAS), Behçet disease (BD), Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis 
(PFAPA) syndrome, and Mouth and Genitals Ulcers with Inflamed Cartilage (MAGIC) syndrome. Aim of the 
present work was to review the literature to evaluate reliability of colchicine against recurrent oral ulcers, either 
idiopathic, or triggered by an underlying systemic disorder. 
Methods: A systematic review was conducted, with the following P.I.C.O. (Patient, Intervention, Control, 
Outcome) question: “In populations with idiopathic or secondary recurrent oral ulcers, is colchicine more 
effective in improving pain and accelerating healing, compared to other intervention or placebo?” 
Results: Heterogeneity between RCTs prevented from meta-analysis. Thus, seven RCTs and 3 OCTs were 
both considered eligible. Four RCTs focused on BD, two RCTs and three OCTs on RAS, and one RCT on 
PFAPA syndrome. Regarding BD, no significant difference between colchicine and placebo was found in two 
of three placebo-controlled RCTs, and similar inefficacy was found in one RCT when compared to ciclosporin. 
One open label RCT showed promising but partial results on colchicine in reducing PFAPA attacks, when 
compared to corticosteroids. Concerning RAS, colchicine appeared less effective than clofazimine, 
thalidomide and dapsone, with outcomes similar to placebo and higher gastric discomfort than prednisolone.   
Conclusion: Role of colchicine as treatment for idiopathic or secondary recurrent oral ulcers is far from being 
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1 INTRODUCTION 
Colchicine is a natural alkaloid derived from two plants of the lily family: Colchicum autunnale and Gloriosa 
superba, respectively known as meadow saffron and glory lily.1 
Due to its anti-inflammatory and anti-mitotic properties, colchicine usage has been expanded in the last decade 
from FMF and gout to a broader spectrum of cardiovascular, and dermatological conditions.2-4  
In oral medicine, colchicine is included in the alternative therapeutic option for idiopathic recurrent aphthous 
stomatitis (RAS), especially when unresponsive to first-line treatments, such as high-potency topical or 
systemic corticosteroids.5,6  
Additionally, colchicine might play a role in preventing oral aphthous-like ulcers secondary to peculiar clinical 
entities, in the form of systemic vasculitis, such as Behçet disease (BD),7,8 or unusual immune-mediated 
disorders, such as Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) 
syndrome9,10 and Mouth and Genitals Ulcers with Inflamed Cartilage (MAGIC) syndrome.11  
Aim of the present work was to carry out a systematic review of the literature on the reliability of colchicine as 
a treatment for recurrent oral ulcers, either idiopathic, or triggered by an underlying systemic disorder. 
 
2 MATERIAL AND METHODS 
2.1 P.I.C.O. QUESTION 
From July 2019 to October 2019, a review of literature was conducted on the use of colchicine on patients with 
recurrent oral ulcers.  The P.I.C.O. (Patient, Intervention, Control, Outcome) question [based on the Preferred 
Reporting Items for Systematic Review and Meta-analysis (PRISMA)] for this investigation was: “In populations 
with idiopathic or secondary recurrent oral ulcers, is colchicine more effective in improving pain and 
accelerating healing, compared to other intervention or placebo?”  
The P.I.C.O. question was then framed as follows:  
• Human patients undergoing treatment with colchicine to accelerate healing of idiopathic or secondary 
recurrent oral ulcers or preventing their occurrence (Patients);  
• Each variety of systemic administration of colchicine, as well as any colchicine-based topical 
formulations for the mouth (Intervention); 
• Human patients undergoing no treatment, being administered with no drug, placebo, topic or systemic 
drugs (Comparison);  
• Efficacy of colchicine in terms of relief from symptoms caused by oral ulcers, such as burning, itching, 
and pain, and effectiveness in accelerating ulcer healing when compared to no drug, placebo, topic or 
systemic drugs (primary Outcome);  
Ability of colchicine to provide a preventive effect, in terms of longer ulcer-free periods when compared to no 
drug, placebo, topic or systemic interventions (secondary Outcome).  
The review was recorded under the PROSPERO registry (registration number CRD42019142599). 
 
2.2 SEARCH STRATEGY 
No initial restriction has been set concerning date of publication. Inclusion criteria were as follows: RCTs, 
written in English, conducted on human patients undergoing treatment with any variety of systemic or topic 
formulation of colchicine to accelerate healing of idiopathic or secondary recurrent oral ulcers or preventing 
their occurrence, compared to patients undergoing either no treatment, or placebo, or other topic or systemic 
drugs.  
Exclusion criteria were the following: case reports, case series, observational studies, prospective studies, 
retrospective studies, reviews; studies not conducted on human patients; papers published in language other 
than English; “not-inherent" studies, defined as such when:  
• Efficacy of colchicine in other fields of medicine was portrayed with no detail on oral ulcers; 
• Colchicine was mentioned as a part of a multi-drug approach, even for oral ulcers, so that it is not 
possible to draw certain conclusions on its standalone efficacy; 
• Oral side effects of colchicine treatment were described. 
MEDLINE, PubMed Central and other NCBI databases associated with the PubMed platform were searched. 
The research was also carried out through the following electronic databases: Cochrane Library, NIH (National 
Institute of Health), Scopus, Web of Science; Up To Date was also scrutinized. 
 
3 RESULTS 
The present review acquired 3890 preliminary results, of which 1423 were duplicates. The remaining 2467 
studies were scrutinized through a first reading of title and abstract. Due to the aforementioned criteria, 2430 
articles were rejected, since 1992 were defined “not inherent”, and 438 were published in language other than 
English.  
The remaining 37 articles underwent full reading: of these, 27 papers – 10 case reports, 7 case series, 5 
retrospective studies, 2 prospective studies, 2 reviews, 1 case-comparative study - had to be excluded, as 
well.  
Finally, seven RCTs and three OCTs remained. RCTs were scrutinized in order to understand if a meta-
analysis could be performed. Due to the heterogeneity of study design, dose and duration of treatment, choice 
of outcomes and clinical scores between the RCTs, a descriptive approach, inclusive of the evidence coming 
from the OCTs, was pursued, in contrast with the initial purposes of a pure RCT, meta-analytic-driven review. 
Figure 1 shows the flow chart of the study selection process. Table 1 shows the number of results obtained 
from each of the electronic databases scrutinized.  
According to these studies, the efficacy of colchicine against oral ulcerations has been experimented among 
patients affected by BD (Table 2), PFAPA (Table 3), and RAS (Table 4).  
 
3.1 SUMMARY OF LITERATURE 
3.1.1 BD 
Four RCTs have tested the efficacy of colchicine against BD, with a concurrent focus on the oral 
manifestations.   
In 1980, Aktulga et al.12 published the first double blind trial concerning colchicine in BD. From an original 
sample of 35 patients with BD, 28 patients were randomly assigned and successfully completed a six-month 
regimen of either colchicine (0.5 mg) or placebo (lactose + phenolpthaleine 60 mg) regimen.  
In detail, 14 patients (13 M, 1 F; mean age: 34.2 ± 7.2 years) were administered with three 0.5 mg capsules 
of colchicine per day, whilst 14 patients (9 M, 5 F; mean age: 33 ± 12.8 years) were given placebo capsules 
with the same dosage. After the first assessment of signs and symptoms, six monthly visits were performed to 
elucidate any change in symptoms or signs of BD. Each aspect of BD was considered separately, including 
aphthous ulcerations, and compared as “improved”, “no change” or “got worse”. No significant differences 
were found between colchicine group and placebo group, concerning the severity and recurrence of oral 
ulcerations (p > 0.05). 
In 1989, Masuda et al.13 published a double-blind trial where colchicine was tested against ciclosporin: 96 
patients were randomly split into two groups of 49 and 47 patients, with the former undergoing treatment with 
1 mg of colchicine per day, and the latter 10 mg/kg of ciclosporin daily, for 16 weeks. Assessment was 
performed weekly, with a four-grade (0-3) score based on frequency and number of lesions. Ciclosporin group 
experienced a significant improvement of oral ulcerations when compared to placebo (p < 0.001).    
In 2001, Yurdakul et al.14 published a double-blind placebo-controlled trial, in which from an original sample of 
116 patients, 84 individuals with BD (45 M, 39 F) were able to complete a 24-month regimen, consisting of 
either 1-2 mg/day of colchicine or 1-2 mg/day of placebo. Each group included 42 patients, with both treatments 
consisting of indistinguishable tablets adjusted to body weight. Treatment consisted of 2 tablets daily for 
patients under 50 Kg, 2-3 tablets daily on alternate days for patients between 50 and 59 Kg, 3 tablets daily for 
patients weighing 60-75 Kg, up to 3 to 4 tablets daily on alternate days for patients weighing 76-84 Kg, and 4 
tablets daily for patients of  ≥ 85 Kg. With the primary outcome consisting of absence of oral ulceration, and 
secondary outcome calculated as difference in the mean number of oral lesions, no significant differences 
were found between colchicine and placebo for both primary and secondary outcome (p > 0.05). In 2009, 
Davatchi et al.15 enrolled 169 patients with BD in a randomized, double-blind, controlled crossover trial. 
Patients were randomly assigned to either colchicine (1 mg/day) or placebo for four months, and then switched 
to the other arm for further four months of treatment.  
With a similar dropout rate within the two groups, statistical analysis could be performed based on the data 
available for 136 patients treated with colchicine and 146 patients administered with placebo. With Iran Behçet 
Disease Dynamic Activity Measure (IBDDAM) being used, attributing one point for every five oral aphthous 
lesions, colchicine was significantly more effective than placebo in reducing the IBBDAM score (p < 0.05).  
 
3.1.2 PFAPA 
In 2016, Butbul et al.16 published a randomized trial on 18 children affected by PFAPA. After a three-month 
period when a regular dose of corticosteroids was the only therapy pursued, the sample was randomly split in 
two groups. A control group I of 10 children continued with no additional therapy, whereas a study group II of 
8 children was administered colchicine treatment for three months.  
Dose was adjusted in accordance to age, varying from 0.5 to 1.5 mg/day. In this study, no specific information 
regarding the oral manifestation of PFAPA was provided, since PFAPA attacks were analysed as a whole.  
Authors reported that the number of PFAPA attacks in the study group was significantly lower when compared 
to the baseline (p < 0.05) and quasi-signficant to control group (p < 0.06).  
 
3.1.3 RAS 
In 2009, de Abreu et al.17 published a randomized controlled partially blind study, in which 66 patients with 
RAS were split in three groups, differentially treated with clofazimine, colchicine and placebo for 60 days and 
monitored for four months.  Interval between the episodes in days, number of lesions, duration in days, 
diameter in cm, pain, and patient satisfaction were evaluated. With no significant difference at baseline, 
clofazimine lead to a significantly greater number of patients with no recurrence when compared to other 
groups, as well as wider interval between episodes, and a more limited duration of each lesion. Conversely, 
more than half of colchicine patients interrupted treatment, with 23-45% experiencing gastrointestinal side 
effects, with 6% of patients giving a high score (8/10 or more) of personal satisfaction.  
In 2010, Pakfetrat et al.18 published a double-blind randomized clinical trial on 34 patients with RAS, equally 
split in two groups of 17 patients, either treated with 0.5 mg/day of colchicine or with 5 mg of prednisolone for 
12 weeks. Diameter and number of lesions, intensity of pain, duration of pain-free intervals, and side effects 
were scrutinized.  
Although both treatments significantly reduced RAS (p < 0.001), no significant differences could be detected 
between the two  protocols, in terms of size and number of lesions, recurrence, pain, and length of pain-free 
intervals. Contrariwise, colchicine lead to a significantly higher occurrence of side effects than prednisolone, 
with up to 52.9% of patients in the colchicine arm experiencing either gastric disorders, vertigo, or headache. 
Prednisolone caused hypertension and headache in two patients, respectively.   
In 1994, Kats et al.19 published a four-month open prospective trial, carried out in 20 patients affected by RAS 
since a mean period of 5.6 years. In the first two months, no drug was administered, and two baseline values, 
such as number of lesions and pain, through a 0-10 scale, were obtained. In the last two months, patients were 
given 1.5 mg of colchicine, leading to a significant reduction of both of the aforesaid parameters (p < 0.001) 
and transient mild side effects, such as diarrhoea, nausea, abdominal pain, and urticaria.  
In 2003, Altinor et al.20 ublished an open placebo-controlled trial whose focus was the effect of colchicine on 
neutrophil functions in patients affected by RAS. Forty-eight patients were split in two groups and treated with 
1.5 mg of colchcine vs 0.5 mg of placebo. With no specifics on the duration of protocol, colchicine was not able 
to provide a significant reduction of recovery period, similarly to placebo (p >0.05 in both groups).   
In 2009, Mimura et al.21 published an open, 4 years clinical trial on consecutive 21 patients with severe RAS. 
Firstly, patients were given systemic prednisone for two weeks, in order to achieve a baseline status. 
Subsequently, one of the four drugs under scrutiny- colchicine (0.5-1.5 mg/day), dapsone (25-100 mg/day), 
pentoxifylline (400 mg thrice a day), thalidomide (100 mg/day) – was attributed to each patient, for at least six 
months. Patients experienced a sudden switch before the six months, whenever side effects occurred. 
thalidomide proved to be the most effective drug, being “excellent” in 7 of 8 patients, followed by dapsone, 
being “excellent” in 5 out of 9 cases. Colchicine provided good results, with an “excellent” and “moderate” 
score experienced in 8 of 10 patients, causing minor gastrointestinal pain and nausea.  
 
4 DISCUSSION 
Based on the findings of the present review, it is not possible to draw solid conclusions regarding the role of 
colchicine as a reliable treatment for each of BD, RAS and PFAPA, due to the heterogeneity of study designs, 
posology dose and duration of treatment, choice of outcomes and clinical scores. 
Concerning the BD-related studies included in the present review, sample size ranged widely from 28 to 169 
patients, as well as duration of treatment varying from 16 weeks to 2 years. Likewise, clinical score varied from 
a simple choice of primary outcome as “absence of oral ulceration”, to the complex and hard-to-replicate ratio 
provided in the paper by Aktulga et al.12  
The placebo-controlled RCTs offered contrasting results, with two of three RCTs showing no significant 
difference between colchicine and placebo in terms of reduction of number or occurrence of oral lesions. On 
the other hand, the study with the largest sample but also with the most questionable design, a crossover trial 
by Davatchi et al.15 with no apparent washout period between the two protocols, revealed greater effectiveness 
of colchicine rather than placebo. Concerning the colchicine vs ciclosporin RCT by Masuda et al.13 although a 
similar profile of inefficacy of colchicine against ciclosporin was displayed, some limitations must be pointed 
out. Firstly, this study provided a generic four grades (0-3) scale used to enumerate frequency and number of 
oral lesions, with no information provided on the baseline oral status nor if the patients were prevented from 
the usage of topical measures. Finally, a generic “alleviated” is used to describe the outcome of the protocols.     
Based on the findings of the present review, it is not possible to draw solid conclusions regarding the role of 
colchicine as a reliable treatment for BD-related oral ulcers, in line with a Cochrane review on therapies for 
oral ulcers by Taylor et al.7 and the latest EULAR recommendations by Leccese et al.8, with no meta-analysis 
available because of heterogeneity of RCTs, biases in the study design, and lack of standardized outcome 
measures.  
The lack of evidence concerning the role of colchicine against oral ulcers caused by PFAPA is even more 
striking, with just one open label RCT available in literature. In this paper, published by Butbul et al.16 partial 
information regarding oral status was provided, with no comparison to oral baseline status, since the primary 
outcome was then described as the mean of overall PFAPA attacks, together with the disease-free intervals.  
Such a restricted evidence can be justified by the relatively low frequency and self-limiting nature of PFAPA. 
Thus, colchicine is usually considered a second-line treatment, when compared to prednisone, in reducing a 
sudden flare,10 and to tonsillectomy, with two small RCTs describing valuable effects of surgery in the 
occurrence and severity of PFAPA flares.22 
With almost no evidence on PFAPA-related oral aspects, colchicine might exert a prophylactic role against 
PFAPA, as suggested Butbul et al.16 In a review published in 2016,23 a specific role for colchicine was 
suggested in treating PFAPA unresponsive to tonsillectomy, or PFAPA flares with a predominant oral 
manifestation, but further evidence is needed to support these claims, as indicated very recently by Gaggiano 
et al.9 
Two RCTs and three OCTs discussing the effectiveness of colchicine against RAS were included in this 
review.17-21 The conspicuous heterogeneity regarding study design, choice of treatment for comparison 
(placebo, other drug or no therapy), duration of treatment, spacing from two months to two years, size of 
sample, ranging from 20 to 66 patients, prevented an evidence-based interpretation of the results. Bearing in 
mind such discrepancies between the studies, colchicine displayed less effectiveness than clofazimine,17 as 
well as thalidomide and dapsone,21 no significant differences from prednisolone18 or placebo,20 and a 
significant objective and subjective improvement only when compared to no therapy.19  
Furthermore, contrasting evidence emerged regarding the safety profile of colchicine. Of the four RCTs 
describing side effects, two mentioned significantly higher and more severe side effects in colchicine group, 
with one17 reporting an accumulated percentage of 61% of patients forced to interrupt treatment ahead of time, 
and the other18 showing 52.9% of the patients under colchicine suffering from gastric disorders, headache and 
vertigo.  
Conversely, Katz et al.19 illustrated mild and transient side effects in just four of the 20 patients enrolled, 
although the same dosage - 1.5 mg/day - and duration of treatment - two months – as the two aforesaid trials 
were deployed. Mild effects were also described in the six months treatment carried out by Mimura et al.21 
where only three of 21 patients were subjected to diarrhoea, which was controlled through small reduction of 
the 1.5 mg/day of colchicine administered.  
No evidence-based guidelines are available regarding which systemic treatment should be considered the 
first-line for cases of RAS unresponsive to topical measures. A Cochrane review focused on the systemic 
intervention for RAS6 collected 25 trials, of which 24 with high or unclear risk of bias, and an inconsistent role 
attributed to the usage of systemic colchicine. These conclusions are in accordance with the findings of the 
present review, and those of a previous systematic review on both topical and systemic treatments against 
RAS.24 
 
5 CONCLUSION  
Despite being widely used in medicine for centuries, the role of colchicine as a treatment for oral ulcers is yet 
to be assessed. Further trials are needed, ideally as RCTs adhering to CONSORT statement. Crossover trials 
are welcomed, especially whenever patients with RAS are to be tested, since this approach is mostly faithful 
to the everyday clinical approach, where clinicians and patients might go through multiple options. However, 
in these cases, an appropriate washout period should be included between treatments. Finally, a thorough 
evaluation of neurological, haematological, nephrological and gastrointestinal repercussions associated with 
colchicine should be consistently outlined and compared to other therapeutic regimens.  
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“colchicine AND oral ulcer” 
 
760  results, classified as follows:  
• 1 case-comparative study; 
• 2 prospective studies;  
• 2 reviews;  
• 5 retrospective studies;  
• 3 OCTs;  
• 7 RCTs;  
• 7 case-series;  
• 9 case-reports;  
• 165 not-in-English;  
• 559 not-inherent studies 
 
54  results, classified as follows: 
• 52 duplicates 
• 1 not-inherent study 








“colchicine AND oral ulcer” 
 
8 results, classified as follows:  
• 5 duplicates 
• 3 not-inherent studies 
 
3  results, classified as follows: 
• 3  duplicates 
 
NIH (National Institute of 
Health) 
 




“colchicine AND oral ulcer” 
 
11  results, classified as follows: 
• 1 duplicate  
• 10 not-inherent studies  
 
52  results, classified as follows: 
• 1 not-in-English 
• 15 duplicates 









1,738  results, classified as follows: 
• 215 not-in-English 















“colchicine AND oral ulcer” 
• 1100 not-inherent studies 
 
534 results, classified as follows: 
• 11 not-inherent studies 
• 5 not-in English 
• 518 duplicates 
 
Up to date  
 




“colchicine AND oral ulcer” 
 
147 results, classified as follows: 
• 46 not-in-English 
• 101 duplicates 
 
149 results, classified as follows: 
• 149 not-inherent studies 
 
Web of Science 
 






“colchicine AND oral ulcer” 
 
326 results, classified as follows: 
• 1 case report 
• 5 not-in-English 
• 118 not-inherent 
• 202 duplicates 
 
108 results, classified as follows: 
• 5 not-inherent studies 











Table 2. Main characteristics of the eligible studies focused on effectiveness of colchicine against oral 
ulcerations related to Behçet disease. 
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Table 3.  Main characteristics of the eligible studies focused on effectiveness of colchicine against oral 
ulcerations related to Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome. 
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group: 4.9 ± 
2.3 at 
baseline vs 
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p = 0.01 
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group: 2.7 ± 
1.5 vs 1.6 ± 
1.2; 










Table 4. Main characteristics of the eligible studies focused on effectiveness of colchicine against oral 
ulcerations related to idiopathic recurrent aphthous stomatitis. 

























(10 M, 10 
F; mean 
age: 21.5 























of lesions by 71%, 
and pain by 77%, 
when compared 
to the previous 
two months with 
no therapy 
 
Number of lesions 
declined from a 
mean of 3.15 ± 
0.88 at baseline, 
to a mean 0.9 ± 
0.72 during 




from a mean of 
7.6 ± 1.19 at 
baseline to a 
mean of 1.85 ± 
1.73 during 














e group I: 
26 
patients 









































(8.25 ± 0.23 days 
at baseline vs 
3.46 ± 028 days 
after treatment; p 
< 0.1) 
 
Placebo group II 
experienced only 
a slight reduction 
(8.05 ± 0.51 days 
at baseline vs 
7.27 ± 0.53 days 














































By 4th month: 17-
44% disease-free 
patients under 



























































with no remission: 
wider intervals, 
less duration of 







the highest profile 
of dissatisfaction: 











































in 7/8 patients 
 































































































pain and nausea 
 
None of the 10 
patients under 
colchicine was 
forced to interrupt 
treatment 













































































number of lesions 










number and size 
group: 17 
patients 













higher in the 
colchicine group 
(52.9% vs 11.8%; 
p 0.027), mostly 
as gastric 
disorders 
         
 
 
Figure 1. Flow-chart of review synthesis. 
 
 
 
 
 
 
 
 
 
